[{"id":"48bd9dcf-d292-48b2-a409-af70759d67b7","acronym":"Brightline-4","url":"https://clinicaltrials.gov/study/NCT06058793","created_at":"2023-09-28T14:10:28.336Z","updated_at":"2025-02-25T15:20:51.763Z","phase":"Phase 3","brief_title":"Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT06058793 - Brightline-4","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 07/07/2025","primary_completion_date":" 07/07/2025","study_txt":" Completion: 07/07/2025","study_completion_date":" 07/07/2025","last_update_posted":"2025-02-10"},{"id":"ed857d81-c1db-430d-8754-fe70af84d781","acronym":"STRASS 2","url":"https://clinicaltrials.gov/study/NCT04031677","created_at":"2021-01-18T19:47:11.156Z","updated_at":"2025-02-25T17:24:14.778Z","phase":"Phase 3","brief_title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","source_id_and_acronym":"NCT04031677 - STRASS 2","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 04/21/2027","primary_completion_date":" 04/21/2027","study_txt":" Completion: 04/21/2028","study_completion_date":" 04/21/2028","last_update_posted":"2025-01-31"},{"id":"1532ca3a-2502-4dd2-b1ac-69ae84a9d9a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04785196","created_at":"2021-03-05T12:55:16.352Z","updated_at":"2024-07-02T16:34:37.707Z","phase":"Phase 1/2","brief_title":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","source_id_and_acronym":"NCT04785196","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-06"},{"id":"8945fb8d-c675-4151-861b-f34bbc81d66c","acronym":"Brightline-1","url":"https://clinicaltrials.gov/study/NCT05218499","created_at":"2022-02-05T18:28:26.477Z","updated_at":"2024-07-02T16:35:02.156Z","phase":"Phase 2/3","brief_title":"Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT05218499 - Brightline-1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 04/16/2024","primary_completion_date":" 04/16/2024","study_txt":" Completion: 05/27/2026","study_completion_date":" 05/27/2026","last_update_posted":"2024-05-22"},{"id":"95af92d3-7ef1-42bc-8075-503c2a4324fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03975387","created_at":"2021-01-18T19:33:08.305Z","updated_at":"2024-07-02T16:35:05.855Z","phase":"Phase 1/2","brief_title":"Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53","source_id_and_acronym":"NCT03975387","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASTX295"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-06"},{"id":"feb3ead4-c6a6-457d-b33b-1a2946c2b846","acronym":"NATARS","url":"https://clinicaltrials.gov/study/NCT05844813","created_at":"2023-05-06T15:04:30.757Z","updated_at":"2024-07-02T16:35:48.112Z","phase":"Phase 4","brief_title":"Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma","source_id_and_acronym":"NCT05844813 - NATARS","lead_sponsor":"Peking University International Hospital","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • doxorubicin hydrochloride • ifosfamide"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 102","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2023-05-12"},{"id":"613e409a-9659-4396-bba3-22b9a39d0fcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877382","created_at":"2021-01-18T08:26:57.296Z","updated_at":"2024-07-02T16:36:37.709Z","phase":"Phase 1","brief_title":"A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT01877382","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" TP53 • MDM2 • GDF15","pipe":" | ","alterations":" TP53 mutation • MDM2 amplification • MDM2 overexpression","tags":["TP53 • MDM2 • GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MDM2 amplification • MDM2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e milademetan (RAIN-32)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 10/08/2020","primary_completion_date":" 10/08/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2020-12-08"},{"id":"592b7eaa-b0b9-44ec-a9e0-7a40a914198a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02264613","created_at":"2021-01-18T10:39:31.889Z","updated_at":"2024-07-02T16:36:43.300Z","phase":"Phase 1/2","brief_title":"ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT02264613","lead_sponsor":"Aileron Therapeutics, Inc.","biomarkers":" TP53 • MDM2 • CDK4","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification • CDK4 amplification","tags":["TP53 • MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2020-07-14"}]